Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol-associated liver disease. WHY IT'S IMPORTANT ...
To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...